Different levels of sensory neuropeptides (calcitonin gene-related peptide and substance P) during and after exercise in man

Clinical Physiology

Volumn 16, Issue 1, 1996, Pages 73-82

  Lind, H ^a   Brudin, L ^b   Lindholm, L ^a   Edvinssont, L ^c  

^a LUND UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CGRP; Diabetes (NIDDM); Exercise; Hypertension; Substance P

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; SUBSTANCE P;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE; EXERCISE TEST; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030047123     PISSN: 01445979     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1475-097X.1996.tb00557.x     Document Type: Article

References (32)

1. ARMITAGE P. (1983) Statistical methods in medical research, pp 206, 217-225. Blackwell Scientific Publications, Oxford.
2. BRODIN E., LINDFORS N. & THEODORSSON-NORHEIM E. (1985) Tachykinins in rat central nervous system: distribution, molecular forms, release and effects of chronic treatment with antidepressant drugs. In: Tachykinin antagonists (eds Håkansson, R. & Sundler, F.), pp 15-27. Eisevier, Amsterdam.
3. BROOKS S., NEVILL M. E., MELEGROS L., LAKOMY H. K., HALL G. M., BLOOM S. R. & WILLIAMS C. (1990) The hormonal responses to repetitive brief maximal exercise in humans. Eur J Appl Physiol, 60, 144-148.
4. EDVINSSON L., EKMAN R. & THULIN T. (1989) Circulating perivascular dilatory neuropeptides in hypertension. J Hypertens, 7 (suppl. 6), 194-195.
5. EDVINSSON L., ERLINGE D., EKMAN R. & THULIN T. (1992) Sensory nerve terminal activity in severe hypertension as reflected by circulating Calcitonin Gene-Related Peptide (CGRP) and Substance P. Blood Pressure, 1, 223-229.
6. FRIED G., TERENIUS L., HOKFELT T. & GOLDSTEIN M. (1985) Evidence for differential localization of noradrenaline and neuropeptide Y (NPY) in neuronal storage vesicles isolated from rat vas deferens. J Neurosci, 5, 450-458.
7. FULLER R. W., MAXWELL D. L., DIXON C. M., MACGREGOR G. P., BARNES V. F., BLOOM S. R. & BARNES P. J. (1987) The effect of Substance P on cardiovascular and respiratory function in normal subjects, J Appl Physiol, 62, 1473-1479.
8. FURCHGOTT R. F. (1984) Role of endothelium in responses of vascular smooth muscle drugs. Rev Pharmacol Toxicol, 24, 175-197.
9. GIBBINS I.,L., FURNESS J. B., COSTA M., MACINTYRE I., HILLYARD C. J. & GIRGIS S. (1985) Co-localisation of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous vascular and visceral sensory neurons of guinea pig. Neurosci Lett, 57, 125-130.
10. GIBSON S. J., POLAK J. M., BLOOM S. R., SABATE I. M., MULDERRY P. M., GATHEI M. A., MACGREGOR G. P., MORRISON J. F. B., KELLY J. S., EVANS R. M. & ROSENFELD M. G. (1984) Calcitonin gene-related peptide immunoreactivity in man and eight other species. J Neurosci, 4, 3101-3111.
11. GOADSBY P. J., EDVINSSON L. & EKMAN R. (1990) Vasoactive peptide release in extracerebral circulation of humans during migraine headache. Ann Neurol, 28, 183-187.
12. GRUNDITZ T., EKMAN R. & HÅKANSON R. (1984) Calcitonin gene-related peptide in thyroid nerve fibres and C-cells. Effect on thyroid hormone secretion and response to Hypercalcimia. Endocrinology, 119, 2313-2324.
13. Guidelines sub-committee of the WHO/IHS mild hypertension liaison committee: 1989 guidelines for the management of mild hypertension: memorandum from a WHO/IHS meeting. (1989). J Hypertens, 7, 689-693.
14. JUUL R., EDVINSSON L., GISVOLD S. E., EKMAN R., BRUBAKK A. & FREDRIKSEN T. (1990) Calcitonin gene-related peptide-LI in subarachnoid haemorrhage in man. Signs of activation of the trigeminocerebrovascular system. Br J Neurosurg, 4, 171-180.
15. LEE Y., TAKAMI K., KAWAI Y., GIRGIS S., HILLYARD J., MACINTYRE I., EMSON P. C. & TOHYAMA M. (1985) Distribution of calcitonin gene-related peptide in the rat peripheral nervous system with reference to its coexistence with substance P. Neuroscience, 15, 1227-1237.
16. LIND H., NILSSON P., HOLTHUIS N. & LINDHOLM L. (1994a) Non-obese men with high lipoprotein (a) values - a cardiovascular risk group different from those with the metabolic syndrome? Scand J Clin Inv, 54, 177-183.
17. LIND H., BRUDIN L., CASTENFORS J., HEDNER T., LINDHOLM L. & EDVINSSON L. (1994b) The effects of α-trinositol on haemodynamic parameters and neuropeptide Y levels in a pilot study of hypertensives and healthy volunteers. Blood Pressure, 3, 242-247.
18. LUNDBERG J. M., MARTINSSON A., HEMSÉN A., THEODORSSON-NORHEIM E., SVEDENHAG J., EKBLOM B. & HJELMDAHL P. (1985) Co-release in Neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun, 133, 30-36.
19. MASUDA A., SHIMAMOTO K., YOSHIHIRO M., NAKAGAVA M., URA N. & IIMURA O. (1992) Plasma calcitonin gene-related peptide levels in patients with various hypertensive disease. J Hypertens, 10, 1499-1504.
20. MATSUYAMA T., WANAKA A., YONEDA S., KIMURA K., GIRGIS S., MACINTYRE I., EMSON P. C. & TOHYAMA M. (1986) Two distinct calcitonin gene-related peptide-containing peripheral nervous systems: Distribu-tion and quantitative differences between the iris and the cerebral artery with reference to substance P. Brain Res, 373, 205-212.
21. NATIONAL BOARD OF HEALTH AND WELFARE DRUG INFORMATION COMMITTEE, SWEDEN (1987). Treatment of mild hypertension. Workshop 1987:1.
22. NORDENFELDT I., ADOLFSSON L., NILSSON J. & OLSSON S. (1985), Reference values for exercise tests with continuous increase in load. Clin Physiol, 5, 161-172.
23. PANZA J. A., QUYYUMI A., BRUSH J. E. & EPSTEIN S. E. (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. New Engl J Med, 323, 22-27.
24. PANZA J. A., CASINO P. R., KILCOYNE C. M. & QUYYUMI A. A. (1994) Impaired endothelium-dependent vasodilation hi patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol, 23 (7), 1610-1616.
25. PORTALUPPI F., TRASFORINI G., MARGUTTI A., VERGNANI L., AMBROSIO M. R., ROSSI R., BAGNI B., PANSINI R. & UBERTI E. C. (1992) Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J Hypertens, 19, 1227-1234.
26. SCHIFTER S., KRUSELL L. R., SEHESTED J. (1991) Normal serum levels of calcitonin gene-related peptide (CGRP) in mild to moderate hypertensives. Am J Hypertens, 4, 565-569.
27. STRUTHERS A. D., BROWN M. J., MACDONALD D. W., BEACHAM J. L., STEVENSSON J. C., MORRIS H. R. & MACINTYRE I. (1986) Human calcitonin gene-related peptide; a potent endogenous vasodilator in man. Clin Sci, 70, 389-393.
28. TIDGREN B., THEODORSSON E. & HJELMDAHL P. (1991) Renal and systemic immunoreactive neuropeptide Y and calcitonin gene-related peptide responses to mental stress and adrenaline in humans. Clin Physiol, 11, 9-19.
29. VALDEMARSSON S., EDVINSSON L., EKMAN R., HEDNER P. & SJOHOLM A. (1991) Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors. J Int Med, 230, 325-331.
30. WALLIN L. & BRUDIN H. (1988) Physical working capacity determined by different types of bicycle exercise tests. Clin Physiol, 8, 529-537.
31. WHO expert committee on Diabetes mellitus: second report. Techn Rep Ser 646. Geneva: WHO, 1990.
32. ZAIDI M. & BEVIS P. J. R. (1991) Enhanced circulating levels of neurally derived calcitonin gene-related peptide in spontaneously hypertensive rats. Cardiovasc Res, 25, 125-128.